EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

Zourab Bebia, Osvaldo Reyes, Robert Jeanfreau, Anu Kantele iD, Ruth Graciela De Leon, Marta García Sánchez, Peyman Banooni, Glenn J Gardener, José Luis Bartha Rasero, Maria Begoña Encinas Pardilla, Joanne M Langley iD, Claudio Maañón Di Leo und 16 weitere

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Zourab Bebia und 27 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a phase 1/2 study, a maternal respiratory syncytial virus vaccine candidate (RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV-specific humoral immune responses in non-pregnant women.

Methods

In this phase 2 observer-blind, placebo-controlled, randomized clinical trial (NCT04126213), the safety of RSVPreF3 (60 or 120 µg), administered during late second or third trimester, was evaluated in 213 18- to 40-year-old healthy pregnant women through 6 months postdelivery and their offspring through infancy; immunogenicity was evaluated through day 43 postdelivery and day 181 postbirth, respectively.

Results

RSVPreF3 was well tolerated. No pregnancy-related or neonatal adverse events of special interest were considered vaccine/placebo related. In the 60 and 120 µg RSVPreF3 groups: (1) neutralizing antibody (nAb) titers in mothers increased 12.7- and 14.9-fold against RSV-A and 10.6- and 13.2-fold against RSV-B, respectively, 1 month postvaccination and remained 8.9–10.0-fold over prevaccination at day 43 postdelivery; (2) nAb titers were consistently higher compared to placebo recipients; (3) placental transfer ratios for anti-RSVPreF3 antibodies at birth were 1.62 and 1.90, respectively, and (4) nAb levels in infants were highest at birth and declined through day 181 postbirth.

Conclusions

RSVPreF3 maternal vaccination had an acceptable safety risk profile and induced robust RSV-specific immune responses with successful antibody transfer to their newborns. Clinical Trials Registration NCT04126213.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus, HumanPregnancyHumansFemaleInfantInfant, NewbornAdolescentYoung AdultAdultAntibodies, ViralAntibodies, NeutralizingMothersViral Fusion ProteinsPlacentaImmunogenicity, Vaccine

Stichwörter der Autor:innen

RSVfetal carehumoral immunitymaternal immunizationneonatal carepassive immunizationplacental transferpregnancypreterm birth

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingViral Fusion Proteins

Autor:innen und Institutionen

  • GSK, Rockville, Maryland, USA.
  • International Vaccination Centre, National Network of Researchers of Panama, Panama, Panama.
  • MedPharmics, Metairie, Louisiana, USA.
  • Meilahti Vaccine Research Centre, Inflammation Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Institute Conmemorativo Gorgas de Estudios de la Salud, Panama, Panama.
  • Hospital Quironsalud Málaga, Málaga, Spain.

ORCID-Profile: Anu Kantele, Joanne M Langley, Elisabeth Botelho-Nevers

Förderung

  • GlaxoSmithKline Biologicals SA

Zitieren

APA

Bebia, Z., Reyes, O., Jeanfreau, R., Kantele, A., De Leon, R. G., Sánchez, M. G., Banooni, P., Gardener, G. J., Rasero, J. L. B., Pardilla, M. B. E., Langley, J. M., Di Leo, C. M., Botelho-Nevers, E., Buttery, J., Laurichesse, H., Madhi, S. A., García, A. M., Stanley, T., Barjat, T., …, & Henry, O. (2023). Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad024

Vancouver

Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, Sánchez MG, et al. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad024

BibTeX
@article{Bebia2023,
  author = {Bebia, Zourab and Reyes, Osvaldo and Jeanfreau, Robert and Kantele, Anu and De Leon, Ruth Graciela and Sánchez, Marta García and Banooni, Peyman and Gardener, Glenn J and Rasero, José Luis Bartha and Pardilla, Maria Begoña Encinas and Langley, Joanne M and Di Leo, Claudio Maañón and Botelho-Nevers, Elisabeth and Buttery, Jim and Laurichesse, Helene and Madhi, Shabir A and García, Adrián Martín and Stanley, Thorsten and Barjat, Tiphaine and Griffith, Rebecca and Castrejón-Alba, Maria Mercedes and de Heusch, Magali and Dieussaert, Ilse and Hercor, Melanie and Lese, Patricia and Qian, Hui and Tullio, Antonella N and Henry, Ouzama},
  title = {Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad024}
}
Kostenlos starten →